3-methyl-2-butanone-2,4,6-triisopropylbenzenesulfonyl-hydrazide | 140226-71-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methyl-2-butanone-2,4,6-triisopropylbenzenesulfonyl-hydrazide
• CAS: 140226-71-7
• 化学式: C₂₀H₃₄N₂O₂S
• 分子量: 366.568
• InChiKey: OHFHORVSDQGIMU-UHFFFAOYSA-N

物化性质

• 沸点：
  443.5±55.0 °C(Predicted)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.37
• 重原子数：
  25.0
• 可旋转键数：
  7.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  58.53
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  3-methyl-2-butanone-2,4,6-triisopropylbenzenesulfonyl-hydrazide 在 正丁基锂 、 sodium hydride 作用下， 反应 9.75h， 生成
  参考文献：
  名称：

  A convergent method for the stereoselective synthesis of trisubstituted alkenes

  摘要：

  A method for the stereoselective, convergent synthesis of trisubstituted alkenes has been developed. The procedure features the synthesis of allylic alcohols 9 by coupling an aldehyde with a vinyl organometallic reagent. Treatment of 9 with carbon disulfide and methyl iodide gave the intermediate allylic xanthates 10 that underwent facile [3,3]-sigmatropic rearrangement to give the dithiocarbonates 11 and 12, radical reduction of which gave the (E)-alkenes 13 as the major products.

  DOI：

  10.1021/jo00035a004
• 作为产物：
  描述：

  2,4,6-三异丙基苯磺酰氯 在 一水合肼 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 5.0h， 生成 3-methyl-2-butanone-2,4,6-triisopropylbenzenesulfonyl-hydrazide
  参考文献：
  名称：

  （-）-Englerins A / B，（+）-Orientalols E / F和（-）-Oxyphyllol的总合成

  摘要：

  由市售材料（R）-（+）-柠檬烯以20个步骤合成（-）-烯绿蛋白A。另外，从该途径的中间体获得了（-）-恩格林B，（+）-东方醇E / F和（-）-羟叶酚。关键步骤包括羟基丙烷立体选择性和区域选择性分子内环丙烷化反应以及多丙烷级立体选择性形式内分子[3 + 2]交叉环加成（[3 + 2] -IMCC）与羰基的环丙烷1,1-二酯。还获得了恩格尔林的7，10-非对映异构体的前体。

  DOI：

  10.1021/acs.orglett.8b00552

文献信息

• [EN] HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROBICYCLIQUES COMME INHIBITEURS DE LA BÊTA-LACTAMASE
  申请人：ASTRAZENECA AB

  公开号：WO2013150296A1

  公开（公告）日：2013-10-10

  The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R 2, R 3 and R 4 are described herein.

  本发明涉及一种β-内酰胺酶抑制剂化合物。这些化合物及其药学上可接受的盐，可与β-内酰胺类抗生素结合使用，或单独使用，用于治疗细菌感染，包括由耐药菌株引起的感染，包括多药耐药菌株引起的感染。本发明包括根据式(Ia)的化合物：或其药学上可接受的盐，其中R1、R2、R3和R4的值如本文所述。
• The reaction of iodine with vinyltrialkylborates derived from trialkylboranes and trisylhydrazones of methyl ketones. A new method for synthesis of 1,1-dialkylethenes
  作者：Kamlakar Avasthi、Tsutomu Baba、Akira Suzuki

  DOI：10.1016/s0040-4039(00)77746-x

  日期：1980.1

  1,1-Dialkylethenes are readily prepared in good yields from vinyltrialkylborates derived from trialkylboranes and trisylhydrazones of methyl ketones by treatment with iodine.

  通过用碘处理，容易地由衍生自甲基酮的三烷基硼烷和三甲tri的三乙烯基硼酸乙烯基酯容易地以高收率制备1，1-二烷基乙烯。
• Desymmetrizing Hydroformylation with the Aid of a Planar Chiral Catalyst-Directing Group
  作者：Bernhard Breit、Daniel Breuninger

  DOI：10.1021/ja0467364

  日期：2004.8.1

  Desymmetrizing hydroformylation of bisalkenyl- and bisallylcarbinols could be achieved employing a chiral substrate-bound catalyst-directing group (o-DPPF) with excellent levels of diastereotopic alkene face and diastereotopic alkene group discrimination to give bifunctionalized chiral aldehydes in enantiomerically pure form.

  双烯基和双烯丙基甲醇的去对称加氢甲酰化可以使用手性底物结合的催化剂导向基团 (o-DPPF) 来实现，该基团具有出色的非对映烯烃面和非对映烯烃基团辨别能力，以得到对映体纯形式的双官能化手性醛。
• Beta-Lactamase Inhibitor Compounds
  申请人：ASTRAZENECA AB

  公开号：US20150073011A1

  公开（公告）日：2015-03-12

  The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R 1 , R 2 , R 3 and R 4 are described herein.

  本发明涉及一种β-内酰胺酶抑制剂化合物。这些化合物及其药学上可接受的盐，与β-内酰胺类抗生素联合使用或单独使用，可用于治疗细菌感染，包括由耐药菌株引起的感染，包括多重耐药菌株。本发明包括公式（Ia）所述的化合物：或其药学上可接受的盐，其中R1、R2、R3和R4的值如本文所述。
• BETA-LACTAMASE INHIBITOR COMPOUNDS
  申请人：Entasis Therapeutics Limited

  公开号：US20160175290A1

  公开（公告）日：2016-06-23

  The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R 1 , R 2 , R 3 and R 4 are described herein.

  本发明涉及一种β-内酰胺酶抑制剂化合物。该化合物及其药学上可接受的盐可与β-内酰胺类抗生素联合使用或单独使用，用于治疗细菌感染，包括由耐药菌引起的感染，包括多重耐药菌。本发明包括根据式（Ia）描述的化合物：或其药学上可接受的盐，其中R1，R2，R3和R4的值如本文所述。